Human thioredoxin, a cellular disulphide reducing protein, is known to be secreted by some types of cells and to display unique extracellular activities including modulation of cytokine actions and protection of the cell against damage from oxidative stress. This study has been undertaken to investigate the pattern of expression and tissue distribution of thioredoxin in human endometrium during the menstrual cycle. Immunohistochemical studies showed increased thioredoxin immunoreactivity in the glands of the secretory phase compared to those of the proliferative phase. Although the staining of thioredoxin was relatively intense in predecidual stromal cells, the most prominent staining of thioredoxin was present in both glands and stroma of the endometrium in the early secretory phase of the menstrual cycle. Northern hybridization analyses revealed that expression of thioredoxin mRNA in the endometrium of the early secretory phase was~3-fold compared to the other phases of the menstrual cycle, consistent with the results of the immunohistochemical studies. These results suggest that both protein and gene expression of thioredoxin in the endometrium are menstrual cycle phase-specific and highly active in the phase of endometrial differentiation which occurs in preparation for implantation (early secretory phase of the menstrual cycle). Thioredoxin expressed in the early secretory phase of the menstrual cycle may be advantageous for blastocyst implantation.
Introduction
Human endometrium exhibits proliferation, differentiation and tissue breakdown during the menstrual cycle under the influence of ovarian steroid hormones (oestrogens and progesterones). A large number of endometrial growth factors and cytokines are involved in this cyclicity and in the preparation for blastocyst implantation (Tabibzadeh, 1991; Giudice, 1994) . During these procedures, reactive oxygen intermediates (ROIs) have been reported to be generated in the endometrium (Riley and Behrman, 1991; Hunt, 1994) . As a possible defence system against this oxidative stress, anti-oxidants including superoxide dismutase (SOD) and Bcl-2 are known to be present in the endometrium and pregnancy decidua, and probably hormonally regulated during the menstrual cycle (Narimoto et al., 1990; Otsuki et al., 1994; Sugino et al., 1996; Lea et al., 1997) .
Thioredoxin (Trx), a cellular redox-active disulphide/dithiol protein, has also been reported to be able to protect the cell against damage from oxidative stress (Schallreuter et al., 1986; Spector et al., 1988; Mitsui et al., 1992) . Trx acts in combination with NADPH and thioredoxin reductase to catalyse protein disulphide reduction and thereby exhibits multiple biological functions including donation of hydrogen for ribonucleotide reductase, catalysis of protein-folding, the degradation of insulin, regulation of glucocorticoid receptor activity, and modulation of DNA-binding activities of transcription factors (Grippo et al., 1985; Holmgren, 1985; Holmgren, 1989; Abate et al., 1990; Makino et al., 1996) .
Human thioredoxin (hTrx) (Teshigawara et al., 1985; Tagaya et al., 1988; Tagaya et al., 1989; Gasdaska et al., 1994) also has multiple extracellular activities including cell growth stimulation (Nakamura et al., 1992; Gasdaska et al., 1995) , co-stimulation of cytokine gene expression (Schenk et al., 1996) , enhancement of cytokine activities (Wakasugi et al., 1990) , and defence against cellular damage caused by oxidative stress Nakamura et al., 1994) . Human Trx has been identified in the female reproductive tissues including (pre)decidual cells (Fujii et al., 1991; Kobayashi et al., 1995) , ovaries (Iwai et al., 1992) , and placenta (Kobayashi et al., 1995) Since hTrx has such unique biological activities, this study was designed to examine its pattern of expression and tissue distribution in the human endometrium during the menstrual cycle by immunohistochemistry and Northern hybridization analysis.
Materials and methods

Tissue collection
For immunohistochemistry, endometrial specimens were obtained from 35 patients at the time of endometrial biopsy or hysterectomy. The specimens were confirmed histologically as normal endometrium. Dat-ing was performed according to the criteria of Noyes et al. (1950) and divided into early to mid proliferative (days 4-9; six cases), late proliferative (days 10-14; six cases), early secretory (days 15-19; three cases), mid secretory (days 20-23; 10 cases), and late secretory phase (days 24-27; 10 cases). Four endometrial specimens in the mid proliferative (day 6), early secretory (day 16), mid secretory (day 21), and late secretory phase (day 28) were immediately snap-frozen in liquid nitrogen, stored at -80°C, and used for Northern blot analyses.
All samples were obtained following the informed consent of the patients. All patients had regular menstrual cycles, and none had received hormone therapy.
Antibodies
A monoclonal antibody against hTrx, ADF-11, was kindly provided by Fujirebio, Inc., Tokyo, Japan (Kogaki et al., 1996) . MOPC-21 (mouse IgG1) was obtained from Sigma, St Louis, MO, USA.
Immunohistochemistry
Specimens were fixed in 10% neutral formalin and embedded in paraffin. Sections 3 µm thick were deparaffinized and the staining procedure was performed using a Biomedia Histoscan Kit (Biomedia Co., Foster City, CA, USA). The sections were incubated with primary antibody at 2 mg/ml for 90 min at 37°C.
After washing, they were incubated with biotinylated anti-mouse IgG and then incubated with a mixture of avidin and biotinylated horseradish peroxidase for 30 min, followed by development with 3-amino-9-ethylcarbazole. The sections were lightly counterstained with haematoxylin. The intensity of staining was evaluated by staining the same specimens several times and observations were performed by more than two observers. Intensity was graded as (-) for no staining, (Ϯ) for weak staining, (ϩ) for moderate staining, and (ϩϩ) for strong staining. The intensity of staining was also evaluated using a pointscoring system: 0 for no staining, 0.5 for weak staining, 1 for moderate staining, and 2 for strong staining. Differences in the scores between the different groups were statistically assessed using analysis of variance with repeated measurements, followed by a Fisher's protected least significant difference multiple-range test. Differences were considered significant if P Ͻ 0.05.
RNA isolation from endometrial tissues and Northern blot hybridization
Frozen endometrial tissues were homogenized with a Dounce homogenizer in 1 ml of TRIzol ® Reagent (Life Technologies, Inc., Grand island, NY, USA) per 100 mg of tissue. Following homogenization, insoluble material from the homogenate was removed by centrifugation at 12 000 g for 10 min at 4°C. Total RNA was extracted using TRIzol ® reagent according to the manufacturer's instruction. Twenty micrograms of total RNA were electrophoresed, transferred to Maximum Strength Nytran ® nylon (Schleicher & Schuell, Keene, NH, USA) by TurboBlotter™ system (Schleicher & Schuell), and the filter was hybridized with the human Trx probe. The presence of equal amounts of total RNA in each lane was verified by visualization of ethidium bromide-stained 28S and 18S ribosomal RNA subunits and by analysis of glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mRNA, using a cDNA probe. The intensity of the signals on Northern blot hybridization analyses was quantitated with NIH Image program version 1.57 using an Apple Macintosh IIci computer (Apple Computers, Cupertino, CA, USA).
Results
Immunohistochemical expression of hTrx
In the early to mid proliferative phase of the menstrual cycle, the glands of the endometrium did not react with hTrx-11 mAb ( Figure 1A ), but stromal cells were stained weakly. In the late proliferative phase, stromal cells and glands were moderately stained for hTrx ( Figure 1B ). In the early secretory phase, both glands and stromal cells showed moderate to strong staining for hTrx ( Figure 1C ). The staining was mainly observed in the nucleus of the glands and stromal cells. However, positively stained cells in the cytoplasm were also intermingled in the glands and stroma. In the mid secretory phase, the staining for hTrx in the glands and stromal cells was observed as well as that in the early secretory phase ( Figure 1D ). In the late secretory phase, the staining in the glands became less intense than that in the early to mid secretory phase (Figure 2 ), but stromal cells transformed into predecidual cells expressed hTrx moderately ( Figure 1E) .
Because different expression of hTrx was observed in the endometrium during the menstrual cycle, the qualitative changes in expression were semi-quantitated using the scoring system of the staining intensity (Figure 2 ). The highest score was observed in the early secretory phase and decreased slightly in the mid to late secretory phase. The score in the proliferative phase was consistently low.
Expression of hTrx mRNA
The endometrial specimens examined for Northern blot analysis revealed a single 0.5 kb band that hybridized to a 540 bp EcoRI fragment of the human thioredoxin cDNA ( Figure 3A) . The RNA extracts from the endometrial specimens in the proliferative phase (day 6; lanes 1-3), mid secretory phase (day 21; lanes 7-9) and late secretory phase (day 28; lanes 10-12) of the menstrual cycle showed weaker hybridization signals than those of the early secretory phase (day 16; lanes 4-6). The relative amount of mRNA in each lane was analysed by densitometry using G3PDH mRNA as an internal control ( Figure 3B ). The hTrx hybridization signal of each lane was normalized by the respective G3PDH absorbance to correct for uneven loading ( Figure 3C ). Approximately 3-fold of the abundance of hTrx mRNA was observed in the endometrium of the early secretory phase compared to other phases of the menstrual cycle.
Discussion
The endometrium shows proliferative activity under the influence of oestrogen during the proliferative phase. After ovulation, the proliferative activity turns into cellular differentiation under the influence of both oestrogen and progesterone in the secretory phase of the menstrual cycle. By immunohistochemical analysis, hTrx was detected in the glands of the late proliferative endometrium. Subsequently the strongest expression of hTrx was observed in the early secretory phase. Moderate expression was maintained during the mid to late secretory phases. The results suggest that hTrx is induced in the glands of the endometrium in the proliferative phase of the menstrual cycle under the influence of oestrogen. The strongest expression of hTrx in the early secretory phase implies that the production of this protein might be accelerated under the cooperation of oestrogen and progesterone. The accelerated production of hTrx in the early secretory phase was confirmed by Northern blot hybridization analysis. Although the immunohistochemical expression of hTrx is main- tained in the glands of the endometrium during the mid to late secretory phases, the level of hTrx mRNA is not increased in these phases by Northern blot hybridization analysis. Therefore, 991 progesterone levels during the secretory phase seem not to be the major factor for the production of hTrx in the endometrium.
In the early secretory phase of the menstrual cycle, the gland Figure 2 . Human Trx staining in the endometrium at different stages of the menstrual cycle. Relative intensity of staining for the epithelial (j) and stromal ( g ) hTrx in 35 endometrial samples during the menstrual cycle. Early to mid proliferative (days 4-9; n ϭ 6), late proliferative (days 10-14; n ϭ 6), early secretory (days 15-19; n ϭ 3), mid secretory (days 20-23; n ϭ 10), and late secretory (days 24-27; n ϭ 10) endometrium. *P Ͻ 0.01, versus early-mid proliferative endometrium. #P Ͻ 0.05, versus late proliferative endometrium. $P Ͻ 0.05, versus early-mid proliferative endometrium. **P Ͻ 0.01, versus late proliferative endometrium.
cells of the proliferative phase become functionally active secretory cells. The expression of hTrx has been reported to occur in the functionally active cells, including ciliated cells of the Fallopian tube, proximal tubules of the kidney, efferent ducts and Leydig cells of the testis (Fujii, et al., 1991) , and lutein cells of the corpus luteum (Iwai et al., 1992) . It is therefore likely that the strongest expression of hTrx occurs in the endometrial glands which are at the functionally most active phase. Human Trx has been shown not only to activate glucocorticoid receptors but also to affect the DNA binding of several transcription factors including NF-κB and AP-1 through its reducing activity (Abate, et al., 1990; Meyer et al., 1993; Schenk et al., 1994) . Given that, it is possible that one of the functions of hTrx in the endometrial glands might be the modulation of the DNAbinding activity of ligand-dependent transcription factors including progesterone receptors (PR). Indeed, endometrial glands commence to differentiate functionally and morphologically in response to the increased level of both serum progesterone and tissue progesterone receptors in the early secretory phase. Moreover, the reduction-oxidation (redox) state has been reported to modulate the DNA-binding activity of PR (Peleg et al., 1988 (Peleg et al., , 1989 . Taken together, hTrx induced in the endometrial glands of the early secretory phase might enhance DNA binding and transcriptional activity of PR in order to accelerate the differentiation of the glands.
We have demonstrated that hTrx expression is prominent in both endometrial glandular and stromal cells in the early secretory phase. It has been reported that Cu,Zn-SOD and Mn-SOD, well-characterized superoxide anion radical scavengers, are expressed preferentially in the epithelial glandular cells throughout the menstrual cycle (Narimoto et al., 1990; Sugino et al., 1996) and that the total SOD activity is the highest in the mid- Figure 3 . Northern blot analysis of RNA expression in human endometrium for thioredoxin (hTrx). Samples of total RNA (20 µg) were extracted from the following tissues and electrophoresed in triplicate: proliferative phase (day 6; lanes 1-3); early secretory phase (day 16; lanes 4-6); mid secretory (day 21; lanes 7-9); late secretory (day 28; lanes 10-12). (A) Autoradiograph of hybridization with the hTrx cDNA probe. (B) Autoradiograph of the same membrane hybridized with the glucose-3-phosphate dehydrogenase (G3PDH) probe. (C) Densitometric analysis of the autoradiographs shown in A and B, using the integrated area under the respective absorbance curves to calculate the hTrx/G3PDH hybridization ratio for each sample. secretory phase (Sugino et al., 1996) . On the other hand, Bcl-2, an anti-apoptosis factor, has been shown to be able to scavenge ROIs (Hockenbery et al., 1993) and to be abundant in proliferative endometrial glands (Otsuki et al., 1994) and in CD56ϩ large granular lymphocytes which infiltrate the early pregnancy decidua (Lea et al., 1997) . It is of great interest that these three anti-oxidants appear to show a different pattern of expression and tissue distribution in cycling endometrium, suggesting that they have a specific, rather than a redundant, role(s) in protection against oxidative stress in the uterine milieu.
Trx as well as SOD has been reported to overcome the mouse 2-cell stage developmental block in vitro, probably by scavenging ROIs (Natsuyama et al., 1992 (Natsuyama et al., , 1993 . Trx has also been suggested to play a role in reproduction as a component of the 'early pregnancy factor' (Clarke et al., 1991) and to promote embryonal development probably by facilitating cysteine uptake (Natsuyama et al., 1992; Takahashi et al., 1993; Iwata et al., 1994) . We have recently demonstrated that target disruption of the mouse thioredoxin gene results in early embryonic lethality, implicating thioredoxin as an essential factor in the morphogenesis of mouse embryo (Matsui et al., 1996) . Thus, the strongest expression of hTrx in the endometrium of the early secretory phase observed in this study might be advantageous for blastocyst implantation and its development. Further analysis on the induction mechanism of endometrial hTrx by ovarian steroids is underway.
